Retatrutide: First Dose to Full Protocol

How the total weekly dose gets distributed changes how the drug behaves, not just how convenient it is. The full section breaks down what weekly, twice weekly, and daily each produce in peak intensity, tolerability, and week-to-week consistency, with the reasoning for why twice weekly is the rational default for most researchers. It also covers why morning injection is a mechanism argument rather than a preference, the thermogenesis and cortisol alignment behind it, and why so many reported side effects are timing problems wearing a dose problem's clothes.

The diagnostic above gives you a read. This section gives you the full logic behind it: the four stall patterns laid out side by side, what each one looks like, what is actually causing it, the correct response, and the wrong response that buries the problem instead of fixing it. Timing failure, lean mass loss, infrastructure drop, and impatience produce nearly identical stalls from the outside, and only one of them warrants adding a compound. It also covers the four interpretation errors that send researchers reacting to the wrong signal in the first place.

The decision to add a support layer should be driven by a specific visible gap the foundation revealed, not by the feeling that a more advanced protocol should produce more. This section lays out the signs the foundation is doing its job against the signs a second variable is warranted, what Tesamorelin actually solves and what it does not, and the eight-week rule for when adding it is rational versus when it is adding complexity to a system you have not finished reading. It also covers the cost of leaving a real bottleneck unaddressed, which is not a neutral choice.

The support compounds put directly next to each other, because the whole problem is that they get ranked by strength instead of matched to a job. What each one is, the research reference ranges, why ipamorelin cannot be run alone and needs a GHRH layer loaded first, and how Tesamorelin plus ipamorelin, CJC no DAC plus ipamorelin, and HGH are three different decisions rather than three strengths of the same one. This is the reference you come back to before deciding what, if anything, the foundation has actually earned.

A stage-by-stage interpretation guide across sixteen weeks, organized around what you are likely to experience, what that experience means, and, critically, what not to do in response to it. The calibration period, the normalization misread that produces most researchers' first crisis, the foundation stabilization window, the earliest rational point to consider a support layer, and the read-and-adjust phase. It also covers how injection timing has to be coordinated once daily support compounds are added on top of a weekly foundation, since that is a timing problem most people do not see coming.

Worked examples showing how the framework translates into a sequenced protocol, and, just as usefully, how it falls apart when the sequence is skipped. The clean staged build where every change is attributable, the protocol where support was added before the foundation was stable, and the overbuilt stack started all at once that feels productive at week one and becomes unreadable at week six. Most researchers find their own situation in one of these, which is faster than reading the theory and applying it cold.

The questions that come up most at this decision point, answered with decision logic rather than a reflexive compound recommendation: whether to add Tesamorelin now, whether ipamorelin is needed too, whether bedtime injection is better, whether HGH is stronger, and why results slowed after week three. It closes with the consolidated research reference ranges and timing logic for every compound in the guide, labelled as reference context rather than direction, so the whole reference sits in one place you can return to.